Patents by Inventor Zarna Patel

Zarna Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cationic polymers
    Patent number: 11975110
    Abstract: Disclosed are cationic polymers comprising monomers such as those described in Formula (I). Such polymers can be useful for the preparation of therapeutic compositions [e.g., compositions comprising nucleic acids such as m RNA). Additionally, therapeutic compositions comprising these cationic, biodegradable polymers can have improved properties and reduced toxicity.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: May 7, 2024
    Assignee: TRANSLATE BIO, INC.
    Inventors: Frank DeRosa, Michael Heartlein, Shrirang Karve, Zarna Patel
  • COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA
    Publication number: 20230226147
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Application
    Filed: December 6, 2022
    Publication date: July 20, 2023
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Composition and methods for treatment of primary ciliary dyskinesia
    Patent number: 11559561
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Grant
    Filed: January 7, 2020
    Date of Patent: January 24, 2023
    Assignee: TRANSLATE BIO, INC.
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Dry Powder Formulations for Messenger RNA
    Publication number: 20230000781
    Abstract: The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
    Type: Application
    Filed: May 16, 2022
    Publication date: January 5, 2023
    Inventors: Frank DeRosa, Michael Heartlein, Shrirang Karve, Zarna Patel, Ashish Sarode
  • PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES
    Publication number: 20220395459
    Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 15, 2022
    Inventors: Shrirang Karve, Zarna Patel, Yi Zhang, Ashish Sarode, Rebecca L. Goldman, Frank DeRosa, Michael Heartlein
  • MESSENGER RNA VACCINES AND USES THEREOF
    Publication number: 20220347307
    Abstract: The present invention provides, among other things, methods and compositions of formulating nucleic acid-containing nanoparticles for efficient delivery of payload in vivo such that the method and compositions can be used to generate mRNA vaccines.
    Type: Application
    Filed: March 28, 2022
    Publication date: November 3, 2022
    Inventors: Shrirang Karve, Zarna Patel, Ashish Sarode, Yi Zhang, Frank DeRosa, Michael Heartlein
  • TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
    Publication number: 20220324926
    Abstract: The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject. The method comprises administering a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein at a concentration of 0.5 mg/mL or greater to a human subject via nebulization. The composition is aerosolized using a nebulizer and a nominal dose of the mRNA is administered to the human subject via the nebulizer over a period of time, typically at least 30 minutes, at a suitable nebulization rate, e.g., at least 0.2 mL/minute.
    Type: Application
    Filed: March 11, 2022
    Publication date: October 13, 2022
    Inventors: Shrirang Karve, Frank DeRosa, Michael Heartlein, Zarna Patel
  • IMPROVED PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES
    Publication number: 20220218612
    Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process for enhanced encapsulation of messenger RNA (mRNA) in lipid nanoparticles comprising a step of heating the mRNA-encapsulated lipid nanoparticles in a drug product formulation solution.
    Type: Application
    Filed: May 14, 2020
    Publication date: July 14, 2022
    Inventors: Shrirang Karve, Frank DeRosa, Michael Hearlein, Ashish Sarode, Zarna Patel, Rebecca L. Ball, Natalia Vargas Montoya, Priyal Patel, Asad Khanmohammed
  • Process of preparing mRNA-loaded lipid nanoparticles
    Patent number: 11357726
    Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: June 14, 2022
    Inventors: Shrirang Karve, Zarna Patel, Yi Zhang, Ashish Sarode, Rebecca L. Goldman, Frank DeRosa, Michael Heartlein
  • TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF CODON-OPTIMIZED mRNA ENCODING CFTR
    Publication number: 20220160827
    Abstract: The present invention provides, among other things, methods of treating cystic fibrosis, comprising a step of administering to a subject in need of treatment a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, wherein the mRNA encoding the CFTR protein comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 1, wherein the mRNA is at a concentration of at least 0.4 mg/mL, and wherein the step of administering comprises inhalation.
    Type: Application
    Filed: October 1, 2021
    Publication date: May 26, 2022
    Inventors: Michael Heartlein, Frank DeRosa, Alan Kimura, Jonathan Abysalh, Anusha Dias, Shrirang Karve, Zarna Patel
  • Composition and Methods for Treatment of Primary Ciliary Dyskinesia
    Publication number: 20220087935
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Application
    Filed: January 7, 2020
    Publication date: March 24, 2022
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • Dry Powder Formulations for Messenger RNA
    Publication number: 20210378977
    Abstract: The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
    Type: Application
    Filed: July 23, 2019
    Publication date: December 9, 2021
    Inventors: Shrirang Karve, Frank DeRosa, Michael Heartlein, Zarna Patel, Ashish Sarode
  • Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
    Patent number: 11173190
    Abstract: The present invention provides, among other things, methods of treating cystic fibrosis, comprising a step of administering to a subject in need of treatment a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, wherein the mRNA encoding the CFTR protein comprises a polynucleotide sequence at least 80% identical to SEQ ID NO: 1, wherein the mRNA is at a concentration of at least 0.4 mg/mL, and wherein the step of administering comprises inhalation.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: November 16, 2021
    Assignee: TRANSLATE BIO, INC.
    Inventors: Michael Heartlein, Frank DeRosa, Alan Kimura, Jonathan Abysalh, Anusha Dias, Shrirang Karve, Zarna Patel
  • MESSENGER RNA THERAPY FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
    Publication number: 20210187122
    Abstract: The present invention provides methods and compositions of treating Friedreich's ataxia (FRDA) based on administering an mRNA encoding a frataxin protein.
    Type: Application
    Filed: September 10, 2020
    Publication date: June 24, 2021
    Inventors: Michael Heartlein, Frank DeRosa, Jonathan Cherry, Paula Lewis, Shrirang Karve, Zarna Patel, Darshan Parekh, Susan Wood, Chi-Sung Chiu, Caroline J. Woo
  • Cationic Polymers
    Publication number: 20210113483
    Abstract: Disclosed are cationic polymers comprising monomers such as those described in Formula (I). Such polymers can be useful for the preparation of therapeutic compositions [e.g., compositions comprising nucleic acids such as m RNA). Additionally, therapeutic compositions comprising these cationic, biodegradable polymers can have improved properties and reduced toxicity.
    Type: Application
    Filed: February 1, 2019
    Publication date: April 22, 2021
    Inventors: Frank DeRosa, Michael Heartlein, Shrirang Karve, Zarna Patel
  • Messenger RNA therapy for the treatment of Friedreich's ataxia
    Patent number: 10780183
    Abstract: The present invention provides methods and compositions of treating Friedreich's ataxia (FRDA) based on administering an mRNA encoding a frataxin protein.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: September 22, 2020
    Assignee: TRANSLATE BIO, INC.
    Inventors: Michael Heartlein, Frank DeRosa, Jonathan Cherry, Paula Lewis, Shrirang Karve, Zarna Patel, Darshan Parekh, Susan Wood, Chi-Sung Chiu, Caroline J. Woo
  • COMPOSITION AND METHODS FOR TREATMENT OF PRIMARY CILIARY DYSKINESIA
    Publication number: 20200215157
    Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Application
    Filed: January 7, 2020
    Publication date: July 9, 2020
    Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
  • TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
    Publication number: 20200157157
    Abstract: The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject. The method comprises administering a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein at a concentration of 0.5 mg/mL or greater to a human subject via nebulization. The composition is aerosolized using a nebulizer and a nominal dose of the mRNA is administered to the human subject via the nebulizer over a period of time, typically at least 30 minutes, at a suitable nebulization rate, e.g., at least 0.2 mL/minute.
    Type: Application
    Filed: November 21, 2019
    Publication date: May 21, 2020
    Inventors: SHRIRANG KARVE, FRANK DEROSA, MICHAEL HEARTLEIN, ZARNA PATEL
  • PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES
    Publication number: 20200085745
    Abstract: The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing a solution of pre-formed lipid nanoparticles and mRNA at a low concentration.
    Type: Application
    Filed: August 28, 2019
    Publication date: March 19, 2020
    Inventors: Shrirang Karve, Zarna Patel, Yi Zhang, Ashish Sarode, Rebecca L. Ball, Frank DeRosa, Michael Heartlein
  • DRY POWDER FORMULATIONS FOR MESSENGER RNA
    Publication number: 20200022921
    Abstract: The present invention provides stable, dry powder messenger RNA formulations for therapeutic use, and methods of making and using the same.
    Type: Application
    Filed: July 23, 2019
    Publication date: January 23, 2020
    Inventors: Shrirang Karve, Frank DeRosa, Michael Heartlein, Zarna Patel, Ashish Sarode